Studies listed as adjuvants for melanoma (including uveal, mucosal and ocular)....not advocating all of them, but adjuvant options are out there...forgive formatting, best I could do! Call the sites if interested!!!

Recruiting	A Phase II Study of Imatinib Versus Interferon as Adjuvant Therapy in KIT-mutated Melanoma   NCT01782508 For-Melanoma, Drug = Imatinib, interferon
Recruiting	A Study of the BRAF Inhibitor Dabrafenib in Combination With the MEK Inhibitor Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma After Surgical Resection.  NCT01682083 For-Melanoma, Drug = Dabrafenib, trametinib, placebo
Recruiting	Adjuvant, Combined Interleukin 2 (Proleukin) and DTIC (Dacarbazine) in High-risk Melanoma Patients   NCT00553618 For-Metastatic Melanoma, Drug = Proleukin, Dacarbazine
Recruiting	Adjuvant Crizotinib in High-Risk Uveal Melanoma Following Definitive Therapy NCT02223819 For-uveal melanoma, Drug = crizotinib
Recruiting	Adjuvant Dabrafenib (GSK2118436) in Patients With Surgically Resected AJCC Stage IIIC Melanoma Characterized by a BRAFV600E/K Mutation NCT01682213 For-Melanoma, Drug = Dabrafenib
Recruiting	Tumor Cell Vaccines and ISCOMATRIX With Chemotherapy After Tumor Removal NCT01341496 For-sarcoma, melanoma epithelial and pleural malignancies.  Drug = Modifies autologous tumor, cyclophosphamide, celecoxib
Recruiting	Phase II/III Clinical Study CSF470 Plus BCG Plus GM-CSF vs IFN Alpha 2b in Stage IIB, IIC and III Melanoma Patients NCT01729663 For-cutaneous mel, Biological-CSF470 vaccine, BCG, molgramostim, Drug-interferon alpha 2b
Not yet recruiting	Study of Neoadjuvant Vemurafenib for BRAF Mutant Melanoma and Palpable Lymph Node Metastasis NCT02036086 For-melanoma, Drug = vemurafenib
Not yet recruiting	Adjuvant Sunitinib or Valproic Acid in High-Risk Patients With Uveal Melanoma NCT02068586, For-ciliary body and choroid melanoma and intraocular mel,Drug-Sunitinib, valproic acid
Recruiting	BRIM8: A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma  NCT01667419, For-mel, Drug = vemurafenib
Recruiting	Ipilimumab for Uveal Melanoma NCT01585194, For-uveal mel, Drug, ipi
Recruiting	Messenger Ribonucleic Acid (mRNA) Transfected Dendritic Cell Vaccination in High Risk Uveal Melanoma Patients NCT00929019, For-uveal mel, Drug = autologous dendritic cells.
Recruiting	Peptide Vaccine and Temozolomide for Metastatic Melanoma Patients NCT01543464, For-malignant mel, Drug = chemo-temozolomide
Recruiting	Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery NCT 01274338 For-recurrent mel, Stages 111B, IIIC, and IV.  Drug = ipi, recombinant interferon
Recruiting	Phase I/II Trial of a Long Peptide Vaccine (LPV7) Plus TLR Agonists NCT02126579, For-mel – metastatic and mucosal.  Drug = peptide vaccine LPV7+tetanus peptide, polyICLC, Resiquimod
Recruiting	Dendritic Cells Plus Autologous Tumor RNA in Uveal Melanoma NCT01983748 For-uveal mel, monosomy 3 positive, no mets.  Drug = autologous dendritic cells
Recruiting	NY-ESO-1 Vaccine in Combination With Ipilimumab in Patients With Unresectable or Metastatic Melanoma NCT01810016 For-unresectable mel.  Drug = ipi, NY-ESO-1protein vaccine, NY-ESO-1OLP4 vaccine
Recruiting	A Phase I Study With a Personalized NeoAntigen Cancer Vaccine in Melanoma NCT01970358 For-mel, Drug = poly-ICLC peptides
Recruiting	Trial of Ipilimumab After Isolated Limb Perfusion, in Patients With Metastases Melanoma NCT02094391 For-in-transit mel Stage IIIB and IIIC. Drug = ipi
Recruiting	Safety and Immunogenicity Study of Multi-phosphopeptide Vaccine Plus PolyICLC in Participants With Melanoma NCT01846143  For-mel, Drug = biological phosphopeptides
Recruiting	A Phase I Trial of a Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma NCT01176474 For – mel. Drug = Nivo, ipi {NOTE – my trial….peptide vaccines no longer given}
Recruiting	Vaccine Therapy and Resiquimod in Treating Patients With Stage II-IV Melanoma That Has Been Removed By Surgery NCT01748747 For-mel, Drug = montanide, MART 1 antigen
Recruiting	Immunotherapy of HLA-A2 Positive Stage II-IV Melanoma Patients NCT01308294. For-mel, Drug = vaccine
Recruiting	Neurotropic Melanoma of the Head and Neck NCT00975520, radiation
Recruiting	Vaccination With Autologous Dendritic Cells Loaded With Autologous Tumor Lysate or Homogenate Combined With Immunomodulating Radiotherapy and/or Preleukapheresis IFN-alfa in Patients With Metastatic Melanoma: a Randomized "Proof-of-principle" Phase II Study NCT01973322 For-nonresectable Stage III or IV mel, Drug = Autologous dendritic cell vaccines, radiation, IFN
Recruiting	CDX-1401 and Poly-ICLC Vaccine Therapy With or Without CDX-301in Treating Patients With Stage IIB-IV Melanoma NCT02129075 For-ciliary body, choroid, extraocular, iris, intraocular, mucosal mel or melanoma Stage IIB – IV Drug = recombinant flt3 ligand, vaccine
Recruiting	A Phase I Study of Intralesional Bacillus Calmette-Guerin (BCG) and Followed by Ipilimumab Therapy in Patients With Advanced Metastatic Melanoma  NCT01838200 For-metastatic mel, Drug = BCG vaccine, ipi
Recruiting	Vaccine Therapy With or Without Interleukin-12 Followed by Daclizumab in Treating Patients With Metastatic Melanoma NCT01307618 For-recurrent mel, stageIV.  Drug = peptide vaccine, MAGE-3.1 antigen, interleukin-12, Mart-1 antigen
Recruiting	Trial of pIL-12 Electroporation Malignant Melanoma NCT01502293 For-mel, Drug=Plasmid interleukin-12
Recruiting	Imiquimod to Detect Residual Lesions and Prevent Recurrence of Lentigo Maligna NCT01088737 For-lentigo maligna, Drug = imiquimod